SCHEMBL1581744

SCHEMBL1581744

CNS(=O)(=O)c1ccc(C(=CC2CCCCC2)CO)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.43
MEN1 O00255 2/20 0.43
LMNA P02545 5/20 0.40
ALDH1A1 P00352 4/20 0.40
TSHR P16473 2/20 0.40
THRB P10828 1/20 0.40
BLM P54132 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
PTGS2 P35354 1/20 0.39
SMN1; SMN2 Q16637 4/20 0.38
GAA P10253 2/20 0.38
CYP3A4 P08684 1/20 0.38
CA12 O43570 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA3 P07451 1/20 0.37
CA4 P22748 1/20 0.37
CA6 P23280 1/20 0.37
CA5A P35218 1/20 0.37
CA7 P43166 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1581741 1.00 KMT2A (0.43) KMT2AMEN1LMNAALDH1A1TSHR
SCHEMBL1581752 0.85 KMT2A (0.49) KMT2AMEN1PTGS2
SCHEMBL4483872 0.85 KMT2A (0.49) KMT2AMEN1PTGS2
SCHEMBL1581754 0.85 KMT2A (0.49) KMT2AMEN1PTGS2
SCHEMBL4486333 0.83 KMT2A (0.47) KMT2APTGS2
SCHEMBL1582005 0.83 KMT2A (0.47) KMT2APTGS2
SCHEMBL1582009 0.83 KMT2A (0.47) KMT2APTGS2
SCHEMBL1582258 0.82 KMT2A (0.35) KMT2AMEN1LMNAALDH1A1TSHR
SCHEMBL1582262 0.82 KMT2A (0.35) KMT2AMEN1LMNAALDH1A1TSHR
SCHEMBL1582260 0.81 NPSR1 (0.36) KMT2AMEN1ALDH1A1THRBCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1585739-B1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS LILLY CO ELI (US) 2011-04-20 EP disclosed
US-7576108-B2 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY (US) 2009-08-18 US disclosed
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators ELI LILLY AND COMPANY 2006-05-25 US disclosed
EP-1585739-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2005-10-19 EP disclosed
WO-2004063179-A1 SUBSTITUTED ARYLCYCLOPROPYLACETAMIDES AS GLUCOKINASE ACTIVATORS ELI LILLY AND COMPANY (US) 2004-07-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111353-A1 Substituted arylcyclopropylacetamides as glucokinase activators GCK, GCKR, GALK1 KMT2A 1603/4885MEN1 4564/4885LMNA 4666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.